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Abstract
Background: Patients diagnosed with neuroendocrine tumors (NETs) with hepatic metastases generally have a worse prognosis
as compared with patients with nonmetastasized NETs. Due to tumor location and distant metastases, a surgical approach is often
not possible and nonsurgical therapeutic strategies may apply.
Objective: The aim of these systematic reviews is to evaluate the role of nonsurgical therapy options for patients with nonresectable
liver metastases of NETs.
Methods: An objective group of librarians will provide an electronic search strategy to examine the MEDLINE, EMBASE, and
The Cochrane Library (Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects, Cochrane Central
Register of Controlled Trials [CENTRAL]) databases. There will be no restriction concerning language and publication date.
The qualitative and quantitative synthesis of the systematic review will be conducted with randomized controlled trials (RCT),
prospective, and retrospective comparative cohort, and case-control studies. Case series will be collected in a separate database
and only used for descriptive purposes.
Results: This study is ongoing and presents a protocol of four systematic reviews to assess the role of nonsurgical treatment
options in patients with neuroendocrine liver metastases.
Conclusions: These systematic reviews, performed according to this protocol, will assess the value of noninvasive therapy
options for patients with nonresectable liver metastases of NETs in combination with invasive techniques, such as percutaneous
liver-directed techniques and local ablation techniques.
Trial Registration: International Prospective Register of Systematic Reviews (PROSPERO): CRD42012002657;
http://www.metaxis.com/PROSPERO/full_doc.asp?RecordID=2657 (Archived by WebCite at
http://www.webcitation.org/6NDlYi37O); CRD42012002658; http://www.metaxis.com/PROSPERO/full_doc.asp?RecordID=2658
(Archived by WebCite at http://www.webcitation.org/6NDlfWSuD); CRD42012002659;
www.metaxis.com/PROSPERO/full_doc.asp?RecordID=2659 (Arichived by Webcite at
h t t p : / / w w w. w e b c i t a t i o n . o r g / 6 N D l m WA F M ) ;  a n d  C R D 4 2 0 1 2 0 0 2 6 6 0 ;
http://www.metaxis.com/PROSPERO/full_doc.asp?RecordID=2660 (Archived by WebCite at
http://www.webcitation.org/6NDmnylzp).
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Introduction
Neuroendocrine Tumors
Neuroendocrine tumors (NET) arise from neuroendocrine cells
and are a heterogeneous group of neoplasms [1-3]. NETs
originate from a wide range of anatomic sites, which are mainly
located in the gastroenteropancreatic system (60%) and the
bronchopulmonary system (>25%) [4,5]. With an incidence of
5.25 per 100,000 each year in the United States, NETs are
considered to be rare tumors [4].
Patients with NET liver metastases either complain of abdominal
pain due to the mass effect of the tumor or excessive hormone
production leading to the carcinoid syndrome, which consists
of diarrhea, cutaneous flushing, various hemodynamic
alterations, and wheezing [6,7]. Moreover, up to 75% of patients
with NETs (including midgut or hindgut origin) present with
liver metastasis at the time of diagnosis [8].
A 5-year survival rate of 22% for patients with NET liver
metastases has been described [5]. Surgical approach shows a
benefit concerning overall survival as compared with the
nonsurgical approach; however, curative surgery is only
applicable in 10% of the patients [9]. Therefore, noninvasive
alternatives, such as local ablation techniques, percutaneous
liver-directed techniques (chemoembolization, bland
embolization, and selective internal radiation therapy), peptide
receptor radionuclide technique, chemotherapy, targeted therapy,
and biotherapy are of great importance and their value has to
be determined.
Local Ablative Techniques
Mechanistically, local ablative techniques such as cryotherapy,
radiofrequency ablation (RFA), and percutaneous alcohol
injection (PEI) rely on the cytotoxic effects of chemicals and
induce nonphysiologic temperatures into the hepatic tissue
[10,11]. Therefore, tumor location and extension in the liver
influences the choice of treatment modality [12].
Percutaneous Liver-Directed Techniques
Treatment modalities involved in percutaneous liver-directed
techniques, include bland embolization (BE), transarterial
chemoembolization (TACE), and selective internal radiation
therapy (SIRT). The principle of BE consists of inducing
regional ischemia to the tumor. In TACE, chemotherapeutic
substances are locally applied causing a cytotoxic effect. Due
to the local embolization the intratumoral concentration of the
cytostatic is as much as 20 times higher using TACE than in
systemically applied chemotherapy [13]. In addition, systemic
side effects can be minimized and cytotoxicity can be maximized
[14]. SIRT uses intracorporal radiation through microspheres
made of glass (Thera-Spheres) or of resins (SIR-Spheres). These
microspheres are loaded with radioactive Yttrium-90 [2]. By
virtue of their size, the microspheres obliterate the vessels and
irradiate the tumor with a high radiation dose. The adjacent
healthy tissue receives minimal dosage [2]. Unfortunately, these
treatment modalities are difficult to compare due to the small
number of patients and to heterogeneous inclusion criteria (eg,
tumor staging, primary tumor location, etc). [15].
Peptide Receptor Radionuclide Therapy
Peptide receptor radionuclide therapy (PRRT), a combination
of a somatostatin analog with a radioligand, a beta-emitter, is
used to detect and treat NETs expressing somatostatin receptors.
After systemic injection, the radioligand is internalized into the
cells and transported to the lysosomes. The effect on tumor cell
proliferation is based on the radiotoxicity of the radionuclide
in the deoxyribonucleic acid of the target cell [16]. However,
radionuclides should be applied cautiously since side effects,
such as bone marrow toxicity, hepatic insufficiency,
myelodysplastic syndrome, renal insufficiency, or hematological
toxicity might occur. Secondary malignancies such as leukemia
are rare, but may also occur [17-19]. Functional imaging (ie,
octreoscan or gallium 68 Positron Emission Tomography [PET])
is required to identify the subgroup of patients eligible for PRRT
[20,21].
Systemic Chemotherapy
The role of systemic chemotherapy for NETs with liver
metastases has been discussed vigorously. In a prospective
study, Moertel et al [22] evaluated streptozotocin as a
chemotherapeutic monotherapy and found a significant response;
however, the benefit was strongly limited by the renal and
hematologic toxicity of streptozotocin, and therefore is not an
acceptable treatment option. Studies combining streptozotocin
with other agents have been conducted with the aim to decrease
the dosage of streptozotocin, and thus reduce its toxicity [23].
For the therapy of metastatic pancreatic NETs, Kouvaraki et al
[24] reported that a combined multidrug chemotherapy with
fluorouracil, doxorubicin, and streptozotocin showed an
acceptable response rate of 39% with responders having both
increased progression-free survival and overall survival.
However, patients with metastatic midgut NETs treated with
this multidrug chemotherapy regimen showed the same survival
rates as interferon-based therapy concepts [25]. Since poorly
differentiated (G3) gastrointestinal NETs behave like lung
neuroendocrine carcinomas (small-cell carcinomas) a
platin-based chemotherapy is discussed [12].
Targeted Therapy
Targeted therapy includes multikinase inhibitors, mammalian
target of rapamycin (mTOR) inhibitors, and monoclonal
antibodies, which interact with various molecular pathways
[26]. Sunitinib, an orally applied multikinase inhibitor, targets
vascular endothelial growth factor (VEGF) receptors as well as
platelet-derived growth factor receptors, which are often
expressed in NETs [27,28]. Everolimus, an mTOR inhibitor,
has also shown antitumor activity [29]. Bevacizumab, a
monoclonal antibody against VEGF, inhibits angiogenesis in
tumors and seems to reduce tumor perfusion [26,30].
Biotherapy
Biotherapy, using interferon-α and somatostatin analogues such
as octreotide and lanreotide, prevents the synthesis of the
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polypeptide hormones and biogenic amines produced by
functional NETs. This provides relief from endocrine symptoms
associated with the carcinoid syndrome in 80% of patients
[31-34]. The Placebo-Controlled, Double-Blind, Prospective,
Randomized Study on the Antiproliferative Efficacy of
Octreotide LAR in the Control of Tumor Growth in Patients
with Metastatic Neuroendocrine Midgut Tumors reports
treatment with octreotide (long-acting release) essentially delays
the period to tumor progression in patients with both functionally
active and inactive metastatic midgut NETs compared with the
placebo-treated group. However, survival analysis could not be
performed due to a small number of observed deaths [35].
The aim of these four systematic reviews is to determine
evidence for the noninvasive treatment options in terms of
symptom relief and tumor control in patients with nonresectable
liver metastases of NETs.
Methods
Systematic Reviews
The following four systematic reviews dealing with the
nonsurgical treatment options of neuroendocrine liver metastases
attempt to address the following questions represented in
Textbox 1.
Our research results will be reported in accordance with the
standards of the Preferred Reporting Items for Systematic
reviews and Meta-Analyses (PRISMA)[36].
The eligibility criteria for inclusion as well as for exclusion of
studies are illustrated in Tables 1-4. Furthermore, the count and
reason of exclusion will be revealed in a flow diagram, which
will comply with the PRISMA Statement 2009 (Figure 1) [36].
The study types that will be included are randomized controlled
trials (RCTs), prospective and retrospective comparative cohort
studies, noncomparative cohort studies, case-control-studies,
and case series.
These studies will provide the basis for the qualitative synthesis
of this systematic review. Single-cohort studies will be collected
in a separate database and will only be used for descriptive
purposes. No publication date or language restrictions will apply.
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Textbox 1. Questions regarding nonsurgical treatment options for neuroendocrine liver metastases.
1. When should locally ablative techniques (RFA, microwave, and cryotherapy) be used in patients with nonresectable neuroendocrine liver metastases?
• Do local ablation techniques (RFA, microwave, and cryotherapy) improve outcome (progression-free survival, overall survival, and quality of
life) in patients with non–resection margin, tumor free (R0)/microscopic tumor lesions (R1) resectable NET liver metastases when compared
with nonablative treatments (resection margin, macroscopic lesion [R2] liver resection, percutaneous liver-directed techniques, peptide receptor
radionuclide treatment, chemotherapy, targeted therapy, and biotherapy)?
• Which local ablation technique (RFA, microwave, and cryotherapy) achieves the best outcome (progression-free survival, overall survival, and
quality of life) in patients with nonresectable NET liver metastases?
• Do local ablation techniques (RFA, microwave, and cryotherapy) in conjunction with a systemic treatment (peptide receptor radionuclide treatment,
chemotherapy, targeted therapy, and biotherapy) improve outcome (progression-free survival, overall survival, and quality of life) in patients
with nonresectable NET liver metastases as opposed to a systemic treatment alone?
• What is the incidence of tumor dissemination in patients with NET liver metastases undergoing a local ablation technique? Does confirmation
occur through imaging/biopsy during the follow-up?
2. When should percutaneous liver-directed techniques be used in patients with nonresectable neuroendocrine liver metastases?
• Do percutaneous liver-directed techniques (bland embolization, chemoembolization, and selective internal radiotherapy) improve outcome
(progression-free survival, overall survival, and quality of life) in patients with nonresectable NET liver metastases as opposed to R2 liver
resection?
• Which percutaneous liver-directed technique (bland embolization, chemoembolization, and selective internal radiotherapy) achieves the best
outcome (progression-free survival, overall survival, and quality of life) in patients with nonresectable NET liver metastases?
• Do percutaneous liver-directed techniques (bland embolization, chemoembolization, selective internal radiotherapy) improve outcome
(progression-free survival, overall survival, and quality of life) in patients with nonresectable NET liver metastases in combination with a systemic
treatment (peptide receptor radionuclide treatment, chemotherapy, targeted therapy, and biotherapy) when compared with a percutaneous
liver-directed technique alone?
• What is the incidence of tumor dissemination in patients with NET liver metastases undergoing a percutaneous liver-directed technique? Does
confirmation occur through imaging/biopsy during the follow-up?
3. When should peptide receptor radionuclide therapy be performed in patients with nonresectable neuroendocrine liver metastases?
• Does a peptide receptor radionuclide therapy improve outcome (progression-free survival, overall survival, and quality of life) in patients with
nonresectable NET liver metastases when compared with R2 liver resection?
• Does the outcome (progression-free survival, overall survival, and quality of life) for patients with nonresectable NET liver metastases undergoing
a peptide receptor radionuclide therapy depend upon the size of liver metastases (>5- vs <5-cm diameter of the largest tumor) or their uptake on
a diagnostic scan?
• Does the outcome (progression-free survival, overall survival, and quality of life) of a peptide receptor radionuclide therapy depend upon the
percentage of liver volume involvement (eg, <75% vs >75%) for patients with nonresectable NET liver metastases?
• Does the outcome (progression free survival, overall survival, and quality of life) of a peptide receptor radionuclide therapy, for patients with
nonresectable NET liver metastases, depend upon the site of the primary tumor?
• Does a peptide receptor radionuclide therapy in combination with percutaneous liver-directed techniques (bland embolization, chemoembolization,
and selective internal radiotherapy) and/or local ablation techniques improve outcome (progression-free survival, overall survival, and quality
of life) in patients with nonresectable NET liver metastases when compared with peptide receptor radionuclide therapy as a single technique?
4. When should chemotherapy, targeted therapy, or biotherapy be used in patients with nonresectable neuroendocrine liver metastases?
• Does chemotherapy, targeted therapy and biotherapy improve outcome (progression-free survival, overall survival, and quality of life) in patients
with nonresectable NET liver metastases as opposed to R2 liver resection?
• Does outcome (progression-free survival, overall survival, and quality of life) of chemotherapy, targeted therapy, and biotherapy in patients with
nonresectable NET liver metastases depend upon the size of liver metastases (>5- vs <5-cm diameter of the largest tumor)?
• Does outcome (progression-free survival, overall survival, and quality of life) of chemotherapy, targeted therapy, and biotherapy in patients with
nonresectable NET liver metastases depend upon the percentage of liver volume involvement (eg, < 75% vs >75%)?
• Does outcome (progression free survival, overall survival, and quality of life) of chemotherapy, targeted therapy, and biotherapy in patients with
nonresectable NET liver metastases depend upon the site of the primary tumor?
• Does chemotherapy, targeted therapy, and biotherapy in combination with percutaneous liver-directed techniques (bland embolization,
chemoembolization, and selective internal radiotherapy) and/or local ablation techniques improve outcome (progression-free survival, overall
survival, and quality of life) in patients with nonresectable NET liver metastases when compared with chemotherapy, targeted therapy, and
biotherapy as a single technique?
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Table 1. Eligibility criteria for review 1: when should locally ablative techniques be used in patients with unresectable neuroendocrine liver metastases?
Exclusion criteriaInclusion criteriaStudy characteristic
Children or adolescents (under the age of 18 years)Patients with nonresectable NLMsaPatients population
Patients that underwent ablation or palliative resec-
tion
Palliative surgical resectionIntervention treatment
Ablation (cryob, RFAc, LITTd, PEIe)
Systemic treatment (chemotherapy, biotherapy, and
targeted therapy)
Surgical resection vs ablationIntervention comparison
Ablative techniques compared with others
Ablation combined with systemic treatment vs abla-
tion only
Case reportsRCTsfStudy design
Prospective and retrospective single- or multicenter
cohort studies
Case series
Overall survival not mentionedReporting
aNeuroendocrine liver metastases
bCryotherapy
cRadiofrequency ablation
dLaser induced thermotherapy
ePercutaneous alcohol injection
fRandomized controlled trials
Table 2. Eligibility criteria for review 2: when should percutaneous liver-directed techniques be used in patients with nonresectable neuroendocrine
liver metastases?
Exclusion criteriaInclusion criteriaStudy characteristic
Children or adolescents (under the age of 18 years)Patients with nonresectable NET liver metastasesPatient population
Patients treated with percutaneous liver directed
techniques
Percutaneous liver directed techniques (bland em-
bolization, chemoembolization, and selective Internal
radiotherapy)
Intervention(s)/ exposure(s)
Palliative liver resectionComparator(s)/ control
Percutaneous liver directed technique with or without
systemic treatment
Case reportsRCTsaStudy design
Prospective and retrospective comparative cohort
studies
Case-control studies
Case series
Studies that do not report the overall survivalPrimary outcome: overall survivalReporting
Secondary outcome: progression-free survival,
quality of life
aRandomized controlled trials
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Table 3. Eligibility criteria for review 3: when should peptide receptor radionuclide therapy be performed in patients with nonresectable neuroendocrine
liver metastases?
Exclusion criteriaInclusion criteriaStudy characteristic
Children or adolescents (under the age of 18 years)Patients with nonresectable liver metastases treated
with peptide receptor radionuclide therapy
Patient population
Peptide receptor radionuclide therapyIntervention–treatment
Percutaneous liver directed techniques (bland em-
bolization, chemoembolization, and selective internal
radiotherapy)
Palliative resection vs peptide receptor radionuclide
therapy
Intervention–comparison
Case reportsRCTsaStudy design
Prospective and retrospective comparative cohort
studies
Noncomparative cohort studies
Case-control studies
Case series
Studies that do not report the overall survivalReporting
aRandomized controlled trials
Table 4. Eligibility criteria for review 4: when should chemotherapy, targeted therapy or biotherapy be used in patients with nonresectable neuroendocrine
liver metastases?
Exclusion criteriaInclusion criteriaStudy characteristic
Children or adolescents (under the age of 18 years)Patients with nonresectable NET liver metastasesPatient population
Patients that underwent chemotherapy or biotherapy
or targeted therapy or palliative liver resection
ChemotherapyIntervention–treatment
Biotherapy
Targeted therapy
Chemotherapy or biotherapy or targeted therapy with
percutaneous liver-directed techniques (bland em-
bolization, chemoembolization, selective internal
radiotherapy)
Chemotherapy or biotherapy or targeted therapy with
locally ablative techniques
Chemotherapy or biotherapy or targeted therapy vs
palliative resection
Intervention–comparison
Chemotherapy or biotherapy or targeted therapy with
percutaneous liver-directed techniques vs single
therapy
Chemotherapy or biotherapy or targeted therapy with
locally ablative techniques vs single therapy
Case reportsRCTsaStudy design
Prospective and retrospective comparative cohort
studies
Noncomparative cohort studies
Case-control studies
Case series
Studies that do not report the overall survivalReporting
aRandomized controlled trials
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Figure 1. Flow diagram according to PRISMA.
Search
The electronic search strategy to scan the databases and detect
all relevant articles was developed by the librarians of the
Medical Library Careum (University of Zurich, Switzerland).
The search will be performed on the MEDLINE, EMBASE,
and The Cochrane Library (Cochrane Database of Systematic
Reviews, Database of Abstracts of Reviews of Effects, and
Cochrane Central Register of Controlled Trials [CENTRAL])
databases. An endnote file, comprising all identified titles and,
if accessible, the corresponding abstracts will be prepared for
the investigators. Supplementary publications will be found by
manual search or by reviewing reference lists. Two independent
review group members will peruse titles and/or abstracts from
studies, which were identified using the search profile.
Afterwards, the entire text of these potentially eligible studies
will be re-examined for eligibility. Any uncertainties will be
discussed and resolved with a third member. A specially created
Web-based, predetermined protocol will be used to extract data
from the included studies for the study quality expertise and
synthesis of medical findings.
Data Extraction
The data extraction parameters, include manuscript title, name
of journal, first author's name, publication year, total number
of  pa t ien ts ,  number  of  pa t ien ts  in  the
chemotherapy/biotherapy/targeted therapy group, number of
patients in the nontreatment group, name of used substances,
age (mean, standard deviation, median), male to female ratio,
progression-free survival, overall survival, quality of life
(containing side effects), study design, and targeting objective
1-5. The Grading of Recommendations Assessment,
Development and Evaluation (GRADE) will be used to grade
the quality (level) of evidence and the strength of
recommendations [37].
We will prepare a narrative synthesis of the findings from the
included studies. A quantitative synthesis will be used if the
included studies are sufficiently homogenous. We anticipate
that there will be a limited scope for meta-analysis of a relatively
large number of studies because of the range of outcomes
measured across the small number of existing trials (such tumors
are rare). Nevertheless, where studies have used the same type
of intervention and comparator, with the same outcome measure,
we will pool the results using a random-effects meta-analysis.
We calculate a 95% CI and two-sided P values for each
outcome.
Results
This study is ongoing and presents a protocol of four systematic
reviews to assess the role of nonsurgical treatment options in
patients with neuroendocrine liver metastases. Both noninvasive
as well as invasive methods, such as percutaneous liver-directed
techniques and local ablation techniques will be investigated.
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Discussion
Several nonsurgical treatment options for neuroendocrine liver
metastases have been reported. However, there is a lack of
consensual data on the subject. These four systematic reviews
described in this protocol aim to clarify the role of nonsurgical
therapy modalities in patients with nonresectable NETs liver
metastases. The systematic reviews will serve as a basis for
developing clinical practice guidelines.
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BE: bland embolization
CENTRAL: Cochrane Central Register of Controlled Trials
GRADE: The Grading of Recommendations Assessment, Development and Evaluation
mTOR: mammalian target of rapamycin
NET: neuroendocrine tumors
PET: Positron Emission Tomography
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
PRRT: peptide receptor radionuclide therapy
R0, R1, R2: resection margin (R0: tumor free; R1: microscopic lesion; R2: macroscopic lesion)
RCT: randomized controlled trial
RFA: radio frequency ablation
SIRT: selective internal radiation therapy
TACE: transarterial chemoembolization
VEGF: vascular endothelial growth factor (receptor)
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